London, UK, and Wilmington, NC, US, January 14, 2013: Chiltern International Limited (Chiltern), a global contract research organization (CRO), announces the appointment of Roger Hunter as Vice President of Strategic Partnerships in the Business Development function.
“It gives me great pleasure to welcome Roger Hunter as Chiltern’s new VP of Strategic Partnerships. Roger comes to us with a strong background in both commercial and development functions within Pharma and Biotech. He has a strong understanding of clinical development and a deep appreciation of the impact that we have on our clients,” stated
Stuart McGuire, VP, Global Business Development.
Roger Hunter added “I look forward to working in close collaboration with our sponsors to develop long standing Strategic Partnerships with them through the delivery of innovative, quality and flexible solutions that address their key needs.”
Roger Hunter has 25 years of experience in the pharmaceutical and biotech industries where his most recent role was VP of Operations with a specialty pharmaceutical company. He holds a BSc (Hons) in Pharmacology from the University of Aberdeen and is field-based in the US.
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs nearly 1,400 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.